Liver alone.

Can patients with hepatocellular carcinoma who progress after sorafenib benefit from immunotherapy? The short answer is not really. In KEYNOTE-240, over 400 patients were randomized to second-line pembrolizumab or…placebo. Median overall survival was 14 months for pembro compared to 11 for placebo, but this did not reach statistical significance. There was also no improvement in progression free survival with a median time of just 3 months to progression in both arms. | Finn, J Clin Oncol 2019


Popular Posts